Navigation Links
Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
Date:5/3/2012

atients with lupus.  The primary endpoint of PEARL-SC requires patients to demonstrate a greater than or equal to five (>5) point reduction in the SELENA/SLEDAI clinical assessment score, no worsening in physician global assessment, and no new BILAG A or two or more new BILAG B organ domain scores.  Details regarding the study can be found at http://www.clinicaltrials.gov.
  • In conjunction with the PEARL-SC DSMB meeting, an independent statistician conducted an interim efficacy analysis after the 350th enrolled patient reached the 24-week time-point of the study. Following the results of the analysis, the statistician recommended the continuation of the PEARL-SC study to completion. The company is expecting final top-line data this quarter.
  • Manufacturing

  • The Company initiated the development of a pre-filled syringe for the self-administration of subcutaneously delivered blisibimod for phase 3 clinical studies. Stability testing is underway.
  • Management

  • Anthera announced the appointment of Dr. Bogdan Dziurzynski to the board of directors. Dr. Dziurzynski currently serves as a strategic regulatory management consultant to the biotechnology industry and serves on the Board of Directors of Dendreon Corporation and the Biologics Consulting Group, Inc.
  • *SELENA/SLEDAI -- Safety of Estrogen in Lupus Erythematosus National Assessment / Systemic Lupus Erythematosus Activity Index is a cumulative, weighted index of systemic lupus erythematosus disease activity.

    About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

    Safe Harbor Statement

    Any statements contained in this press release that refer to future events or other non-historical matters, including stateme
    '/>"/>

    SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/24/2015)... 24, 2015  Bayer Corporation hosted its annual "Take Your ... Bayer HealthCare US headquarters.  This is Bayer,s second "Take Your ... Whippany campus, and Thursday,s event welcomed 230 children ... at work. Fortunately, for the kids, this was ... whose mission is "Science For A Better Life," Bayer made ...
    (Date:4/24/2015)... , April 24, 2015 In today,s ... employee groups around the world to access diverse ... hours. While there are many areas to misstep ... examine which best practices are necessary and beneficial ... According to research by benchmarking firm, ...
    (Date:4/24/2015)... and Markets ( http://www.researchandmarkets.com/research/pmbmv2/global_biobanking ) has announced ... report to their offering. The analysts ... CAGR of 7.07% over the period 2014-2019 ... segments: Equipment and Consumables. This report covers the present ... market for the period 2015-2019. ...
    Breaking Medicine Technology:Bayer Hosts "Take Your Child to Work Day" 2Bayer Hosts "Take Your Child to Work Day" 3Bayer Hosts "Take Your Child to Work Day" 4Work Around the Clock: Building Effective Global Capabilities 2Global Biobanking Market Report 2015-2019 - Increase in Strategic Collaborations with Beckman Coulter, Tecan & Thermo Fischer Scientific Dominating 2
    ... May 2, 2011 NewCardio, Inc., (OTC BB: NWCI) a ... prestigious NYC Bright Lights Conference at the Le Parker Meridien ... of its kind with an exclusive focus on publicly traded ... will present on May 10, 2011 at 9 a.m. ET. ...
    ... Fla., May 2, 2011 The Unilens Vision Inc. ... of Directors today declared a quarterly cash dividend of $0.045 per ... record at the close of business on May 13, 2011. ... Specialty Contact Lens Company" Established in 1989, Unilens ...
    Cached Medicine Technology:NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City on May 10, 2011 2NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City on May 10, 2011 3NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City on May 10, 2011 4Unilens Vision Inc. Declares Quarterly Cash Dividend of $0.045 Per Share 2
    (Date:4/27/2015)... April 27, 2015 The Mount Sinai ... seamless referral process for the Health System’s care providers. ... failure or diabetes, for instance, may have more than ... coordinate with many other care providers. With medical practices ... thousands of patients each year, the need for an ...
    (Date:4/27/2015)... (PRWEB) April 27, 2015 Healthpointe clinics ... treatments for nail fungi and infections. Onychomycosis, which is ... up to 10% of adults in the Western population. ... irregularity in thickness. , Healthpointe’s Anaheim clinic ... a branch dedicated to providing quality skincare products and ...
    (Date:4/27/2015)... The Global Pharmaceutical Packaging Market 2015 – ... 5.9% during the period 2015 – 2019. Plastics will ... packaging market, mainly due to their cost effectiveness and ... is extremely fragmented with the presence of several global ... market with the rest being occupied by several international ...
    (Date:4/27/2015)... Texas has saved $433 million by converting ... providing drug offenders with addiction treatment, according to an ... Several states, including Massachusetts, are considering adopting justice reinvestment ... formed community recovery programs to help redress rampant addiction ... State Governments WA, ID, NE, KS, MI, PA, ...
    (Date:4/27/2015)... Los Angeles gummy smile doctor , ... treatments. “Some people have too much gum tissue and ... purely cosmetic issue that can happen to anyone.” Gummy ... more of the natural tooth structure for a more ... the underlying bone and create a more harmonious facial ...
    Breaking Medicine News(10 mins):Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3Health News:Southern California Healthpointe Clinics Now Treating Nail Fungus 2Health News:Global Pharmaceutical Packaging Market to Grow at 5% CAGR to 2019 Says a New Report at RnRMarketResearch.com 2Health News:Global Pharmaceutical Packaging Market to Grow at 5% CAGR to 2019 Says a New Report at RnRMarketResearch.com 3Health News:Global Pharmaceutical Packaging Market to Grow at 5% CAGR to 2019 Says a New Report at RnRMarketResearch.com 4Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 3Health News:Los Angeles Periodontist, Dr. Sharyar Baradaran, Now Offers Comprehensive Treatments to Correct Gummy Smiles 2
    ... March 27 Otsuka American,Pharmaceutical Inc., the U.S. ... has agreed to pay more than,$4 million to ... drug, for "off-label" uses, the Justice Department announced,today., ... entered into an agreement,with Bristol-Myers Squibb (BMS) to ...
    ... infections , , THURSDAY, March 27 (HealthDay News) -- ... been determined by biologists at Purdue University in Indiana. ... infects more than 50 million people a year and ... is prevalent in Southeast Asia, Central America and South ...
    ... lab would carry therapeutic cells to their destination in ... A "mini stem cell lab" created by U.S. researchers ... biological applications, as well as in the design of ... The team at the Institute for BioNanotechnology in Medicine ...
    ... Electronics Ltd.,(NYSE: TEL ; BSX: TEL) today presented ... support the construction of a new Fisher House(TM) at,Womack ... senior,vice president of Tyco Electronics and head of the ... Electronics,materials manager associate who just returned from a one-year ...
    ... WASHINGTON, March 27 The Men,s Health Policy,Center, ... Health Network,(MHN), announced today that they are hosting ... for Medicare and Medicaid Services (CMS) practice,that unfairly ... "This petition allows people who are impacted ...
    ... American women, SAN DIEGO, March 27 How ... Clinton despite the physical and emotional strain she,s,experienced on ... Clinton, who is making a historic presidential bid. Her ... recently posed,similar questions to its members in a study, ...
    Cached Medicine News:Health News:Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify 2Health News:Biologists Discover How Dengue Virus Matures 2Health News:Researchers Create Protective Sac for Growing Stem Cells 2Health News:Tyco Electronics Contributes $25,000 Towards Construction of New Fisher House(TM) at Ft. Bragg 2Health News:Men's Health Policy Center Hosts Petition to Protest Government Barrier to Prostate Cancer Medications 2Health News:What Drives Hillary to Get Up Every Morning and Hit the Campaign Trail? 2
    Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
    Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
    ... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
    Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
    Medicine Products: